BioNxt Solutions Inc. (CSE:BNXT)

Canada flag Canada · Delayed Price · Currency is CAD
0.5500
-0.0400 (-6.78%)
Jul 18, 2025, 3:44 PM EDT
86.44%
Market Cap64.33M
Revenue (ttm)22.85K
Net Income (ttm)-5.71M
Shares Out116.96M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume82,000
Average Volume67,666
Open0.5700
Previous Close0.5900
Day's Range0.5500 - 0.5700
52-Week Range0.1800 - 0.6900
Beta1.58
RSI49.13
Earnings DateAug 27, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a... [Read more]

Sector Healthcare
Founded 2017
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol BNXT
Full Company Profile

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial Statements

News

There is no news available yet.